Full Text Journal Articles by
Author Beatrice Rendenbach Mueller


Find full text journal articles

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, ,

<h4>Background</h4>Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.<h4>Methods</h4>We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):182-192]

Cited: 0 times

View full text PDF listing >>

Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies.

Hoi-Kei Lon, Nuno Mendonca, Sandra Goss, Ahmed A Othman, Ahmed A Othman, Charles Locke, Ziyi Jin, Beatrice Rendenbach-Mueller,

Alicapistat is an orally active selective inhibitor of calpain 1 and 2 whose overactivation has been linked to Alzheimer disease (AD). Three studies were conducted in healthy subjects (18-55 years), 1 in healthy elderly subjects (≥65 years), and 1 in patients with mild to moderate AD. Four studies assessed pharmacokinetics, 1 study ... Read more >>

Clin Pharmacol Drug Dev (Clinical pharmacology in drug development)
[2019, 8(3):290-303]

Cited: 1 time

View full text PDF listing >>


Mitigating the Metabolic Liability of Carbonyl Reduction: Novel Calpain Inhibitors with P1' Extension.

Andreas Kling, Katja Jantos, Helmut Mack, Wilfried Hornberger, Gisela Backfisch, Yanbin Lao, Marjoleen Nijsen, Beatrice Rendenbach-Mueller, Achim Moeller,

Dysregulation of calpains 1 and 2 has been implicated in a variety of pathological disorders including ischemia/reperfusion injuries, kidney diseases, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). 2-(3-Phenyl-1H)-pyrazol-1-yl)nicotinamides represent a series of novel and potent calpain inhibitors with high selectivity and in vivo efficacy. However, carbonyl reduction ... Read more >>

ACS Med Chem Lett (ACS medicinal chemistry letters)
[2018, 9(3):221-226]

Cited: 0 times

View full text PDF listing >>

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.

Megan L Ryan, Daniel E Falk, Joanne B Fertig, Beatrice Rendenbach-Mueller, David A Katz, Katherine A Tracy, Eric C Strain, Kelly E Dunn, Kyle Kampman, Elizabeth Mahoney, Domenic A Ciraulo, Laurie Sickles-Colaneri, Nassima Ait-Daoud, Bankole A Johnson, Janet Ransom, Charles Scott, George F Koob, Raye Z Litten,

Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. This study evaluated the novel compound, ABT-436, a V1b receptor antagonist, in alcohol-dependent participants ... Read more >>

Neuropsychopharmacology (Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology)
[2017, 42(5):1012-1023]

Cited: 27 times

View full text PDF listing >>

Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials.

Katie Witkiewitz, Daniel E Falk, Henry R Kranzler, Raye Z Litten, Kevin A Hallgren, Stephanie S O'Malley, Raymond F Anton, ,

<h4>Background</h4>Attrition is common in alcohol clinical trials and the resultant loss of data represents an important methodological problem. In the absence of a simulation study, the drinking outcomes among those who are lost to follow-up are not known. Individuals who drop out of treatment and continue to provide drinking data, ... Read more >>

Alcohol Clin Exp Res (Alcoholism, clinical and experimental research)
[2014, 38(11):2826-2834]

Cited: 26 times

View full text PDF listing >>

Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.

Daniel E Falk, Raye Z Litten, Raymond F Anton, Henry R Kranzler, Bankole A Johnson, ,

<h4>Objective</h4>Several definitions of treatment response have been proposed for alcohol clinical trials (e.g., abstinence and no heavy drinking). However, each of these outcomes allows only one definition of successful response. In contrast, the cumulative proportion of responders analysis (CPRA) includes all of the possible drinking response cutoff points, providing a ... Read more >>

J Stud Alcohol Drugs (Journal of studies on alcohol and drugs)
[2014, 75(2):335-346]

Cited: 7 times

View full text PDF listing >>

What happens when people discontinue taking medications? Lessons from COMBINE.

Robert L Stout, Jordan M Braciszewski, Meenakshi Sabina Subbaraman, Henry R Kranzler, Stephanie S O'Malley, Daniel Falk, ,

<h4>Aims</h4>We use intensive longitudinal data methods to illuminate processes affecting patients' drinking in relation to the discontinuation of medications within an alcohol treatment study. Although previous work has focused on broad measures of medication adherence, we focus on dynamic changes in drinking both before and after patients discontinue.<h4>Design</h4>We conducted secondary ... Read more >>

Addiction (Addiction (Abingdon, England))
[2014, 109(12):2044-2052]

Cited: 2 times

View full text PDF listing >>

A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.

Laura Redden, Beatrice Rendenbach-Mueller, Walid M Abi-Saab, David A Katz, Armen Goenjian, Weining Z Robieson, Yaqin Wang, Sandra L Goss, Nicholas Greco, Mario D Saltarelli,

There is substantial preclinical and clinical evidence to suggest a potential role for the dopamine D₃ receptor in the treatment of schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. This double-blind, randomized, placebo-controlled, escalating-dose, parallel-group ... Read more >>

J Clin Psychopharmacol (Journal of clinical psychopharmacology)
[2011, 31(2):221-225]

Cited: 18 times

View full text PDF listing >>


0.7287 s